Compare ICL & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICL | GRFS |
|---|---|---|
| Founded | 1968 | 1940 |
| Country | Israel | Spain |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.2B |
| IPO Year | N/A | 2006 |
| Metric | ICL | GRFS |
|---|---|---|
| Price | $5.57 | $9.49 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 2 |
| Target Price | $6.23 | ★ $10.15 |
| AVG Volume (30 Days) | ★ 1.0M | 452.1K |
| Earning Date | 02-25-2026 | 07-28-2022 |
| Dividend Yield | ★ 3.48% | 1.50% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.29 | ★ 0.64 |
| Revenue | $7,053,000,000.00 | ★ $8,821,017,248.00 |
| Revenue This Year | $5.82 | $5.36 |
| Revenue Next Year | $5.42 | $5.15 |
| P/E Ratio | $19.37 | ★ $18.71 |
| Revenue Growth | 1.77 | ★ 7.31 |
| 52 Week Low | $4.85 | $6.19 |
| 52 Week High | $7.35 | $11.14 |
| Indicator | ICL | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 55.60 | 63.67 |
| Support Level | $4.95 | $9.17 |
| Resistance Level | $5.84 | $9.46 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 68.54 | 88.64 |
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and growing solutions. These segments all contribute to the company's development of agriculture, food, and engineered material products and services. Maximum revenue is generated from its phosphate solutions segment which uses phosphate commodity products, such as phosphate rock and fertilizer-grade phosphoric acid (green phosphoric acid), to produce specialty products. This segment also produces and markets phosphate-based fertilizers. Geographically, the company generates maximum revenue from Brazil followed by, the United States of America, China, United Kingdom, Germany, Spain, Israel, France, India, Netherlands, and other countries.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.